Amarantus Bioscience Holdings Inc (AMBS)

[Solantey]

It's quite possible that if the F.D.A. decides not to approve Mannkind's Afrezza on July 15 or approves it with a bad label, with significant REMS requirements, and also requires periodic lung function testing for all users that Amarantus could possibly acquire Mannkind in a year or two.

If Mannkind doesn't find a marketing partner for Afrezza and has to market Afrezza "in-house" I think as Adam Feuerstein stated, "the commercial launch of Afrezza will be a disaster".

Although Mannkind hasn't found anyone interested in its Technosphere drug delivery system even though they've had it for more than a decade it still may be of some interest to Amarantus as the company always seems ready to acquire new products.